Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

Cancer

Volumn 115, Issue 16, 2009, Pages 3709-3718

  Alvarado, Yesid ^a   Kantarjian, Hagop ^a   O'Brien, Susan ^a   Faderl, Stefan ^a   Borthakur, Gautam ^a   Burger, Jan ^a   Wierda, William ^a   Garcia Manero, Guillermo ^a   Shan, Jianqin ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myeloid leukemia; Chronic phase; Imatinib; Suboptimal response

Indexed keywords

IMATINIB; PEGINTERFERON ALPHA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SCORING SYSTEM; SOKAL RISK SCORE; TREATMENT DURATION; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 68549098145     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24418     Document Type: Article

References (20)

1. Hochhaus A, Druker B, Larson R, O'Brien SG, Gathmann I, Guilhot F. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2007;110:15a. Abstract 25.
2. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
3. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-3546.
4. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200-1206.
5. Druker B, Guilhot F, O'Brien SG, Larson RA. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol. 2006;24(18 suppl):6506.
6. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
7. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878.
8. Quintas-Cardama A, Kantarjian HM, Ravandi F, et al. Immune modulation of minimal residual disease (MRD) in patients (pts) with chronic myelogenous leukemia (CML) in early chronic phase (CP): a randomized trial of frontline high-dose (HS) imatinib mesylate (IM) with or without pegylated-interferon (PEG-IFN) and GM-CSF [abstract]. Blood. 2006;108:626a. Abstract 2207.
9. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425-3432.
10. Kaplan EL, Maier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1965;53:457-481.
11. Snedecor G, Cochran W. Statistical Methods. 7th ed. Ames, IA: Iowa State University Press; 1980.
12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year followup of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
13. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosomepositive chronic myeloid leukemia after failure of interferon-{alpha}. Blood. 2003;102:83-86.
14. Cortes J, Giles F, Salvado A, et al. High-dose imatinib in patients with previously untreated chronic myeloid leukemia in early chronic phase: preliminary results of a multicenter community based trial [abstract]. J Clin Oncol. 2005;23(16 suppl):564s. Abstract 6518.
15. Hughes T, Branford S, Matthews J, et al. Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase [abstract]. Blood. 2003;102:31. Abstract 95.
16. Rosti G, Martinelli G, Castagnetti F, et al. Imatinib 800 mg: preliminary results of a phase II trial of the GIMEMA CML Working Party in intermediate Sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high Sokal risk patients [abstract]. Blood. 2005;106. Abstract 1098.
17. Jain N, Kantarjian H, Fava C, et al. Imatinib dose can be safely reduced after complete cytogenetic response (CCyR) in patients (pts) with chronic myeloid leukemia (CML) in early chronic phase (CP) treated with high-dose imatinib [abstract]. Blood. 2007;110. Abstract 1043.
18. Cortes J, O'Brien S, Jabbour E, et al. Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood. 2007;110. Abstract 29.
19. Cortes J, O'Brien S, Jones D, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood. 2007;110. Abstract 30.
20. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437-4444.